Social determinants of health and newer glucose-lowering drugs adoption among US Medicare beneficiaries with type 2 diabetes.

IF 2.3 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Wei-Han Chen, Yujia Li, Aokun Chen, John M Allen, Yi Guo, Lori Bilello, Steven M Smith, Lanting Yang, Amie J Goodin, Jiang Bian, Jingchuan Guo
{"title":"Social determinants of health and newer glucose-lowering drugs adoption among US Medicare beneficiaries with type 2 diabetes.","authors":"Wei-Han Chen, Yujia Li, Aokun Chen, John M Allen, Yi Guo, Lori Bilello, Steven M Smith, Lanting Yang, Amie J Goodin, Jiang Bian, Jingchuan Guo","doi":"10.18553/jmcp.2024.30.11.1298","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Two classes of newer glucose-lowering drugs (GLDs), sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, improve cardiovascular and renal outcomes among patients with type 2 diabetes (T2D). However, racial and ethnic minority groups carry higher cardiovascular risks but have lower access to newer GLDs. Contextual-level social determinants of health (SDOH) may be the underlying factor associated with newer GLD adoption.</p><p><strong>Objective: </strong>To identify the association between contextual-level SDOH and real-world adoption of newer GLDs among Medicare beneficiaries and to examine the nonstationarity in the associations.</p><p><strong>Methods: </strong>Data were from 15% random samples of January 2017 to December 2018 nationwide Medicare beneficiaries. We identified patients with T2D who did not use newer GLDs in the year before the index date-January 1, 2018-and followed the cohort for 1 year to record their status of initiating a newer GLD. We used a geographically weighted multivariable Poisson regression model to determine to what extent the SDOH-newer GLD initiation association (β coefficient) varied geographically.</p><p><strong>Results: </strong>We identified 795,469 eligible Medicare beneficiaries with T2D during the study period from our dataset. Of the study cohort, mean age was 73.1 (SD = 10.5) years, 424,312 (53.3%) were female, 562,994 (70.8%) were non-Hispanic White, 96,891 (12.2%) were non-Hispanic Black, 84,744 (10.6%) were Hispanic, and 29,645 (3.7%) were Asian/Pacific Islander. Newer GLD initiation was negatively associated with the percentage of the population reporting non-Hispanic Black race, Hispanic ethnicity, and unemployment, as revealed by nonspatial regression analyses. The county-level median household income was also associated with higher newer GLD initiation. The spatial analysis presented distinct distributions of local parameter estimates for each contextual-level SDOH.</p><p><strong>Conclusions: </strong>We identified key contextual-level SDOH associated with real-world adoption of newer GLDs and explored their geographic variation through spatially explicit, data-driven analytical approaches. Identifying areas of strong association between SDOH and newer GLD initiation is crucial for policymakers to allocate resources and develop interventions that address structural inequities.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"30 11","pages":"1298-1307"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of managed care & specialty pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18553/jmcp.2024.30.11.1298","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Two classes of newer glucose-lowering drugs (GLDs), sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, improve cardiovascular and renal outcomes among patients with type 2 diabetes (T2D). However, racial and ethnic minority groups carry higher cardiovascular risks but have lower access to newer GLDs. Contextual-level social determinants of health (SDOH) may be the underlying factor associated with newer GLD adoption.

Objective: To identify the association between contextual-level SDOH and real-world adoption of newer GLDs among Medicare beneficiaries and to examine the nonstationarity in the associations.

Methods: Data were from 15% random samples of January 2017 to December 2018 nationwide Medicare beneficiaries. We identified patients with T2D who did not use newer GLDs in the year before the index date-January 1, 2018-and followed the cohort for 1 year to record their status of initiating a newer GLD. We used a geographically weighted multivariable Poisson regression model to determine to what extent the SDOH-newer GLD initiation association (β coefficient) varied geographically.

Results: We identified 795,469 eligible Medicare beneficiaries with T2D during the study period from our dataset. Of the study cohort, mean age was 73.1 (SD = 10.5) years, 424,312 (53.3%) were female, 562,994 (70.8%) were non-Hispanic White, 96,891 (12.2%) were non-Hispanic Black, 84,744 (10.6%) were Hispanic, and 29,645 (3.7%) were Asian/Pacific Islander. Newer GLD initiation was negatively associated with the percentage of the population reporting non-Hispanic Black race, Hispanic ethnicity, and unemployment, as revealed by nonspatial regression analyses. The county-level median household income was also associated with higher newer GLD initiation. The spatial analysis presented distinct distributions of local parameter estimates for each contextual-level SDOH.

Conclusions: We identified key contextual-level SDOH associated with real-world adoption of newer GLDs and explored their geographic variation through spatially explicit, data-driven analytical approaches. Identifying areas of strong association between SDOH and newer GLD initiation is crucial for policymakers to allocate resources and develop interventions that address structural inequities.

美国 2 型糖尿病医疗保险受益人的健康社会决定因素与新型降糖药物的采用。
背景:钠-葡萄糖共转运体-2抑制剂和胰高血糖素样肽-1受体激动剂这两类新型降糖药(GLDs)可改善2型糖尿病(T2D)患者的心血管和肾脏预后。然而,少数种族和少数族裔群体的心血管风险较高,但获得新型 GLDs 的机会较少。环境层面的健康社会决定因素(SDOH)可能是与采用新型 GLD 相关的潜在因素:确定医疗保险受益人中环境层面的 SDOH 与现实世界中采用较新 GLD 之间的关联,并研究关联中的非平稳性:数据来自 2017 年 1 月至 2018 年 12 月全国医疗保险受益人的 15% 随机样本。我们确定了在指数日期前一年(2018 年 1 月 1 日)未使用较新 GLD 的 T2D 患者,并对该队列进行了为期 1 年的随访,以记录他们开始使用较新 GLD 的情况。我们使用了一个地理加权多变量泊松回归模型来确定SDOH-较新GLD启动关联(β系数)的地理差异程度:我们从数据集中确定了 795,469 名在研究期间患有 T2D 的合格医疗保险受益人。在研究队列中,平均年龄为 73.1 岁(SD = 10.5),424,312 人(53.3%)为女性,562,994 人(70.8%)为非西班牙裔白人,96,891 人(12.2%)为非西班牙裔黑人,84,744 人(10.6%)为西班牙裔,29,645 人(3.7%)为亚洲/太平洋岛民。非空间回归分析表明,较新的 GLD 启动与非西班牙裔黑人、西班牙裔和失业人口比例呈负相关。县级家庭收入中位数也与较高的较新 GLD 启动率有关。空间分析表明,每种背景水平的 SDOH 的地方参数估计值都有不同的分布:我们确定了与现实世界中采用较新的 GLD 相关的关键背景级 SDOH,并通过空间明确、数据驱动的分析方法探讨了其地理差异。对于政策制定者来说,确定 SDOH 与采用较新 GLD 之间存在密切联系的地区对于分配资源和制定干预措施以解决结构性不平等问题至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of managed care & specialty pharmacy
Journal of managed care & specialty pharmacy Health Professions-Pharmacy
CiteScore
3.50
自引率
4.80%
发文量
131
期刊介绍: JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信